SCYNEXIS (SCYX)
Develops antifungal and rare-disease drug candidates under a GSK licensing model.
Something off on this page? Send us feedback.
Develops antifungal and rare-disease drug candidates, including SCY-247 and SCY-770. GSK holds the license to develop and commercialize ibrexafungerp/BREXAFEMME in most markets, leaving SCYNEXIS focused on its clinical pipeline and the planned ADPKD program.
Develops antifungal and rare-disease drug candidates. Its fungerp platform includes SCY-247, while GSK holds an exclusive license to develop and commercialize ibrexafungerp/BREXAFEMME in most markets. Ibrexafungerp received FDA approvals for vulvovaginal candidiasis and reducing recurrence, but it is not a direct-sales product line for SCYNEXIS in the GSK territory.
The pipeline also includes SCY-770, a direct AMPK activator with FDA orphan-drug designation for ADPKD and a planned proof-of-concept study. The company's post-license model depends on GSK's development and commercialization activities in the licensed territory and on clinical execution for SCY-247 and SCY-770.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $54.1M · Total debt $1.9M · Total assets $75.0M · Shareholders' equity $66.9M
- Revenue
- $235.0K
- Operating income
- −$7.8M
- Net income
- $7.4M
No dividends on record.
| Institutions39 holders · as of Jun 30, 2026 | 51.74% | 5.15M shares | |
| Insiders9 holders · as of Jun 30, 2026 | 3.61% | 359.6K shares | |
| Otherremainder | 44.65% | 4.44M shares |
9.95M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (9.95M in the company's Sep 3, 2026 report, 6.29M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Adage Capital Management, L.P.Institution | 10.47% | 1.04M | 13Gfiled Aug 12, 2026 ↗ |
Great Point Partners LLCInstitution | 9.49% | 944,292 | 13Fas of Jun 30, 2026 |
Squadron Capital Management LLCInstitution | 7.61% | 756,884 | 13Fas of Jun 30, 2026 |
Adage Capital Partners GP, L.L.C.Institution | 5.46% | 543,478 | 13Fas of Jun 30, 2026 |
Propel Bio Management, LLCInstitution | 5.46% | 543,478 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 1, 2026 | Gonzalez David Angulo | director, officer: Chief Executive Officer | +217,390 | $1.20 |
- Pfizer
Invasive-Candida treatment overlap through ERAXIS
- Merck
Invasive fungal-infection prevention overlap through NOXAFIL
- Gilead Sciences
Hospital antifungal overlap through AMBISOME
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SCYNEXIS | $5.30 | +2.51% | $32.8M | — | — | 1.7 | −82.8% |
| Pfizer | $29.00 | −0.10% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Merck | $151.58 | −0.04% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Gilead Sciences | $149.00 | −0.41% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Median | 79.8 | 16.5 | 5.6 | +5.1% |